ESTRING (estradiol) by Pfizer is estrogen receptor agonists [moa]. First approved in 1996.
Drug data last refreshed 1h ago
ESTRING is an extended-release vaginal insert containing estradiol, a small-molecule estrogen receptor agonist approved in 1996 by Pfizer. It is indicated for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, delivering localized hormone therapy directly to affected tissues. The product works through estrogen receptor agonism to restore vaginal epithelial health and alleviate atrophic symptoms. It represents a non-systemic alternative to oral or transdermal hormone replacement therapy for women seeking localized vaginal treatment.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on ESTRING at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPfizer is hiring 1 role related to this product
ESTRING supports 492 currently open job roles across Pfizer, reflecting ongoing commercial, medical, and field operations despite the product's LOE_APPROACHING status. Roles likely include brand managers, medical science liaisons (MSLs), specialty sales representatives, market access specialists, and clinical operations personnel focused on defending market share against generics and newer competitors. Key skills demanded include knowledge of menopause treatment algorithms, managed care and formulary negotiation, women's health specialty sales expertise, and ability to differentiate a mature product in an increasingly generic-dominated market.